Benitec Biopharma Inc. (BNTC) AI Stock Analysis
BNTC AI stock analysis summary
AI ResearchBenitec Biopharma Inc. (BNTC) is a clinical-stage biotechnology company developing DNA-directed RNA interference therapies. The company holds a strong cash cushion of $180.0M with minimal debt of $762,000, but generates minimal commercial revenue, reporting trailing twelve-month revenue of $7,000. With ongoing clinical development, BNTC remains unprofitable, posting a trailing twelve-month net loss with an EPS of -$0.98.
- Market cap
- $282.9M
- Revenue (TTM)
- $7,000
- P/E
- —
- 1Y return
- -48.3% S&P 500 16.8%
- Avg. target
- $24.33 200.0% vs last close
Bull case
- The company holds $180.0M in cash and short-term investments alongside total debt of just $762,000 as of June 30, 2026.
- Wall Street analysts maintain 6 Strong Buy ratings with an average price target of $24.33, representing 200.0% upside above the $8.11 share price.
- Benitec Biopharma maintains a high liquidity profile reflected by a current ratio of 34.00 and a debt-to-equity ratio of 0.00.
Bear case
- The company generated only $7,000 in trailing twelve-month revenue and consensus estimates project $0 in revenue for the fiscal year ending June 30, 2027.
- Shareholders experienced significant equity dilution, as the 5-year share count increased by 2321.5%.
- Free cash flow remained negative at -$19.6M in FY2024, driven by ongoing clinical research and development costs.
What Benitec Biopharma does
Benitec Biopharma Inc., headquartered in Hayward, California, is a developmental-stage biotechnology company focused on advancing novel genetic medicines. Founded in 1995, the company specializes in DNA-directed RNA interference (RNAi) therapies to address chronic and life-threatening human conditions. Its primary pipeline initiative includes BB-301, an investigational gene therapy agent based on adeno-associated virus technology designed to treat oculopharyngeal muscular dystrophy. Benitec Biopharma continues to conduct research and development to pioneer transformative treatments in genetic-based therapeutics.
Growth and profitability
Benitec Biopharma generated $216,000 in revenue in FY2024, representing 188.0% growth over FY2023 revenue of $75,000. Across the preceding years, revenue was $97,000 in FY2020, $59,000 in FY2021, and $73,000 in FY2022, reflecting a 5-year revenue CAGR of -58.5%. Due to clinical development expenses, operating margin stood at -10412.0% in FY2024, while net income was -$21.8M with an EPS of -$8.36, compared to net income of -$8.3M in FY2020. In the latest quarter ended June 30, 2026, quarterly revenue grew 12.5% year-over-year, while trailing twelve-month revenue totaled $7,000 and EPS stood at -$0.98.
Balance sheet and cash flow
As of June 30, 2026, Benitec Biopharma reported $180.0M in cash and short-term investments against total debt of $762,000, resulting in net cash of $179.2M. The company maintains strong liquidity with a current ratio of 34.00 and a debt-to-equity ratio of 0.00. In FY2024, free cash flow was -$19.6M, worsening from -$7.6M in FY2020. Capital expenditures were $105,000 in FY2026, and its 5-year share count change expanded by 2321.5% to fund ongoing operations.
Valuation and performance
With a market capitalization of $282.9M and an enterprise value of $164.4M, Benitec Biopharma trades at a price-to-book multiple of 1.9x and an EV-to-EBITDA multiple of 850.9x. This EV-to-EBITDA multiple is substantially higher than the median of its US-listed Healthcare peers of 12.0x. Over the past year, the stock fell 48.3%, underperforming the S&P 500 index return of 16.8%. Over a 5-year horizon, the shares have declined 86.7%, compared to an 83.0% gain for the broader market index.
What analysts expect
Wall Street coverage shows 6 Strong Buy and 1 Buy ratings, with zero Hold, Sell, or Strong Sell recommendations. The mean price target is $24.33, implying an upside of 200.0% from the last close of $8.11. For the current fiscal year ending June 30, 2027, consensus estimates forecast an EPS of -$1.18 and revenue of $0. Benitec Biopharma beat EPS expectations in 2 of the last 4 quarters, and its next earnings release is scheduled for November 13, 2026.
Key risks and what to watch
- Ongoing negative cash flow, including free cash flow of -$19.6M in FY2024, requires monitoring to assess ongoing development spending.
- Heavy past equity dilution indicated by a 2321.5% 5-year share count change highlights risks of future capital raises.
- Share price volatility has seen the stock decline 30.8% below its 200-day moving average and drop 48.3% over the past year.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this BNTC AI stock analysis
This page is an AI-written research summary of Benitec Biopharma Inc. (BNTC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: BNTC income statement, BNTC balance sheet, BNTC key metrics, BNTC analyst forecast, BNTC chart. See the BNTC stock overview for the latest quote and news.
BNTC AI stock analysis FAQ
Does Benitec Biopharma pay a dividend?
Benitec Biopharma does not pay a dividend. The company directs its capital toward research and clinical development.
What is Benitec Biopharma's net cash position?
As of June 30, 2026, Benitec Biopharma held $180.0M in cash and short-term investments and $762,000 in debt, providing net cash of $179.2M.
What do analysts predict for BNTC stock?
Analysts have 6 Strong Buy ratings and 1 Buy rating on BNTC, with a mean price target of $24.33, which is 200.0% above its last close of $8.11.
When is Benitec Biopharma's next earnings report?
The company is scheduled to report its next financial results on November 13, 2026.